What evidence supports the use of atropine in cardiac arrest?

Atropine Has No Role in Cardiac Arrest Management

Atropine should NOT be used routinely during cardiac arrest for PEA or asystole, as current evidence demonstrates it provides no survival benefit and was removed from cardiac arrest algorithms in 2010. 1, 2, 3

Current Guideline Recommendations

The 2015 and 2010 American Heart Association guidelines are unequivocal on this issue:

• "Available evidence suggests that routine use of atropine during PEA or asystole is unlikely to have a therapeutic benefit (Class IIb, LOE B)" 1, 2
• Atropine was removed from the cardiac arrest algorithm in 2010 3
• The 2010 International Consensus states: "There is no convincing evidence that the routine use of other drugs (atropine, amiodarone, lidocaine, procainamide, bretylium, magnesium, buffers, calcium, hormones, or fibrinolytics) during human CPR increases survival to hospital discharge" 4

Evidence Base

What the Research Shows:

No prospective controlled trials have examined atropine use in asystole or bradycardic PEA cardiac arrest 3. The available lower-level evidence is conflicting and shows no meaningful benefit:

• In-hospital cardiac arrest study (2019): Among 20,499 non-shockable arrests, removal of atropine from guidelines was not associated with any change in survival to hospital discharge (risk difference: 2.0% per year, p=0.17) 5

• Out-of-hospital asystole (2011): In 6,419 adults with asystole, atropine with epinephrine increased ROSC (adjusted OR 1.6) but showed no improvement in 30-day favorable neurological outcome (adjusted OR 0.6, p=0.37) 6

• PEA patients (2011): In 1,029 adults with PEA, atropine showed no benefit for ROSC or neurological outcome and was associated with significantly lower 30-day survival (adjusted OR 0.4, p=0.016) 6

• Mixed results (2019): One Japanese study suggested atropine 1mg following epinephrine improved survival to hospital admission for non-shockable rhythms (OR 1.33), but this was not powered for long-term outcomes and contradicts larger studies 7

The Nuance:

While one observational study 7 showed improved ROSC with atropine, this finding is outweighed by:

1. Larger, more rigorous studies showing no survival benefit 5, 6
2. The lack of any improvement in the outcomes that matter most: survival to discharge and neurological function
3. Potential harm in PEA patients 6

Where Atropine DOES Have a Role

Atropine remains indicated for symptomatic bradycardia (NOT cardiac arrest):

• Hemodynamically unstable bradycardia with signs of shock, altered mental status, chest pain, or acute heart failure 2, 8
• Dose: 0.5-1 mg IV, repeated every 3-5 minutes to maximum 3 mg 9, 8
• First-line agent before considering transcutaneous pacing or vasopressor infusions 2, 8

Critical Distinction:

Symptomatic bradycardia with a pulse ≠ Cardiac arrest (pulseless)

The FDA label 10 lists "bradyasystolic cardiac arrest" as an indication, but this reflects older practice patterns that have been superseded by evidence-based guidelines showing no benefit.

Common Pitfalls to Avoid

1. Don't confuse bradycardia management with cardiac arrest management - atropine works for the former, not the latter
2. Don't delay high-quality CPR and defibrillation to establish vascular access for atropine - these interventions actually improve survival 11
3. Don't use doses <0.5 mg - paradoxical bradycardia can occur 9
4. Don't use in heart transplant patients - 20% risk of paradoxical heart block or sinus arrest 12

What to Do Instead During Cardiac Arrest

For non-shockable rhythms (PEA/asystole):

• High-quality CPR with minimal interruptions
• Epinephrine 1 mg IV/IO every 3-5 minutes as soon as feasible 1
• Identify and treat reversible causes (H's and T's)
• Consider advanced airway management

For shockable rhythms (VF/pVT):

• Immediate defibrillation
• High-quality CPR
• Epinephrine after initial defibrillation attempts fail
• Amiodarone 300 mg IV/IO for refractory VF/pVT 1, 11
• Lidocaine as alternative if amiodarone unavailable 1

The evidence is clear: focus on proven interventions (CPR quality, early defibrillation, epinephrine, treating reversible causes) rather than atropine, which adds no survival benefit in cardiac arrest.